CN101622009B - 流感疫苗制剂 - Google Patents

流感疫苗制剂 Download PDF

Info

Publication number
CN101622009B
CN101622009B CN2007800489232A CN200780048923A CN101622009B CN 101622009 B CN101622009 B CN 101622009B CN 2007800489232 A CN2007800489232 A CN 2007800489232A CN 200780048923 A CN200780048923 A CN 200780048923A CN 101622009 B CN101622009 B CN 101622009B
Authority
CN
China
Prior art keywords
ser
asn
lys
gly
influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800489232A
Other languages
English (en)
Chinese (zh)
Other versions
CN101622009A (zh
Inventor
安德烈·奥格雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Variation Biotechnologies Inc
Original Assignee
Variation Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Variation Biotechnologies Inc filed Critical Variation Biotechnologies Inc
Publication of CN101622009A publication Critical patent/CN101622009A/zh
Application granted granted Critical
Publication of CN101622009B publication Critical patent/CN101622009B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN2007800489232A 2006-11-30 2007-11-30 流感疫苗制剂 Expired - Fee Related CN101622009B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86800806P 2006-11-30 2006-11-30
US60/868,008 2006-11-30
PCT/CA2007/002164 WO2008064488A1 (en) 2006-11-30 2007-11-30 Influenza vaccine formulation

Publications (2)

Publication Number Publication Date
CN101622009A CN101622009A (zh) 2010-01-06
CN101622009B true CN101622009B (zh) 2012-08-22

Family

ID=39467397

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800489232A Expired - Fee Related CN101622009B (zh) 2006-11-30 2007-11-30 流感疫苗制剂

Country Status (6)

Country Link
US (2) US7807173B2 (https=)
EP (1) EP2097103B1 (https=)
JP (1) JP5177451B2 (https=)
CN (1) CN101622009B (https=)
CA (1) CA2670965C (https=)
WO (1) WO2008064488A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5177451B2 (ja) * 2006-11-30 2013-04-03 ヴァリエーション バイオテクノロジーズ インコーポレイテッド インフルエンザワクチン製剤
CA2735724C (en) 2008-06-19 2018-07-24 Variation Biotechnologies Inc. Compositions and methods for treating influenza
WO2011138032A2 (en) * 2010-05-05 2011-11-10 Artemev, Timur Universal influenza vaccines and methods for their generation
US20140328876A1 (en) 2011-11-18 2014-11-06 Variation Biotechnologies Inc. Synthetic derivatives of mpl and uses thereof
JP2018528191A (ja) * 2015-08-19 2018-09-27 ラトガーズ， ザ ステイト ユニバーシティ オブ ニュー ジャージー 抗体を生成する新規な方法
NZ751966A (en) 2016-09-20 2023-03-31 Boehringer Ingelheim Vetmedica Gmbh New promoters

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1338308A (zh) * 2000-08-10 2002-03-06 清华大学 一种合成肽流感疫苗及其制备方法
CN1625409A (zh) * 2002-02-08 2005-06-08 变异生物技术公司 含可变肽表位的免疫原制剂及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7118874B2 (en) * 1998-10-09 2006-10-10 Variation Biotechnologies Inc. Immunogenic formulation and process for preparation thereof
US6896881B1 (en) * 1999-09-24 2005-05-24 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
KR20050114225A (ko) * 2003-03-07 2005-12-05 머크 앤드 캄파니 인코포레이티드 인플루엔자 바이러스 백신
MX2007015105A (es) * 2005-06-01 2008-03-18 Variation Biotechnologies Inc Formulacion de vacuna de influenza a base de peptido.
CA2627105A1 (en) * 2005-10-26 2007-05-03 Protelix, Inc. Influenza combinatorial antigen vaccine
EP1951862B1 (en) * 2005-11-07 2013-07-24 MicroVAX, LLC Cd40 ligand fusion protein vaccine
KR20090101883A (ko) * 2006-10-10 2009-09-29 더 거번먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 레프리젠티드 바이 더 세크러터리 오브 더 디파트먼트 오브 헬쓰 앤드 휴먼 써비시즈 조류 인플루엔자 백신
JP5177451B2 (ja) * 2006-11-30 2013-04-03 ヴァリエーション バイオテクノロジーズ インコーポレイテッド インフルエンザワクチン製剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1338308A (zh) * 2000-08-10 2002-03-06 清华大学 一种合成肽流感疫苗及其制备方法
CN1625409A (zh) * 2002-02-08 2005-06-08 变异生物技术公司 含可变肽表位的免疫原制剂及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Katz J.等.Pathogenesis of and immunity to avian influenza A H5 viruses.《Biomedicine & Pharmacotherapy》.Elsevier,2000,第54卷第178-187页. *

Also Published As

Publication number Publication date
US20080193472A1 (en) 2008-08-14
CN101622009A (zh) 2010-01-06
EP2097103B1 (en) 2012-10-03
CA2670965A1 (en) 2008-06-05
WO2008064488A1 (en) 2008-06-05
EP2097103A4 (en) 2010-02-24
US7807173B2 (en) 2010-10-05
US20110020381A1 (en) 2011-01-27
JP5177451B2 (ja) 2013-04-03
JP2010510994A (ja) 2010-04-08
EP2097103A1 (en) 2009-09-09
CA2670965C (en) 2015-02-24

Similar Documents

Publication Publication Date Title
CN107074912B (zh) 流行性感冒病毒疫苗及其用途
US9133247B2 (en) Replikin peptides in rapid replication of glioma cells and in influenza epidemics
CN105452270B (zh) 流行性感冒病毒疫苗及其用途
CN101622009B (zh) 流感疫苗制剂
CN101227919B (zh) 基于肽的流感疫苗制剂
CN106661091B (zh) 流行性感冒病毒疫苗及其用途
CN105237629B (zh) 流感抑制组合物和方法
EP1636254A2 (en) Replikin peptides and uses thereof
JP2008524261A (ja) インフルエンザウイルスタンパク質の組成物およびその使用方法
Kanegae et al. Origin and evolutionary pathways of the H1 hemagglutinin gene of avian, swine and human influenza viruses: cocirculation of two distinct lineages of swine virus
AU2026200025A1 (en) Immunogenic composition
AU2008311897B2 (en) Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes
CN101652385A (zh) Replikin肽及其用途
KR20210135261A (ko) 인플루엔자 ha 스플릿 백신의 제조 방법
RU2358981C2 (ru) Универсальная вакцина против вируса гриппа птиц
WO2013082531A2 (en) Broad spectrum influenza a neutralizing vaccines and d-peptidic compounds, and methods for making and using the same
US20100068224A1 (en) Method for Producing Viral Vaccine and Therapeutic Peptide Antigens
Stepanova et al. Amino acid substitutions N123D and N149D in hemagglutinin molecule enhance immunigenicity of live attenuated influenza H7N9 vaccine strain in experiment
Smirnov et al. Influenza H5 virus escape mutants: immune protection and antibody production in mice
TW201100094A (en) An antigenic peptide derived from influenza virus and a method for selecting anti-influenza virus antibody
CN111163801A (zh) 用于流感病毒的基于乙型肝炎纳米颗粒的疫苗
RU2757013C2 (ru) Рекомбинантная противогриппозная вакцина с широким спектром защиты и способ ее получения
CN114057852A (zh) 一种预防新型冠状病毒肺炎covid-19的多肽及其用途
HK1141032A (en) Replikin peptides and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee
CP02 Change in the address of a patent holder

Address after: Ontario, Canada

Patentee after: Variation Biotechnologies Inc.

Address before: Quebec

Patentee before: Variation Biotechnologies Inc.

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120822

Termination date: 20161130